Global Mesenchymal Stem Cell Therapy Market Size Likely to Expand at a CAGR of 12.7% By 2033

Global Mesenchymal Stem Cell Therapy Market size was valued at USD 3.4 Billion in 2024 and is expected to reach USD 7.7 Billion by 2033, at a CAGR of 12.7% during the forecast period 2024 – 2033.

Mesenchymal Stem Cell Therapy Market: Overview

Mesenchymal stem cell treatment is a sort of regenerative medicine that uses multipotent cells capable of developing into a variety of cell types. MSC treatment commonly uses stem cells derived from bone marrow, adipose tissue (fat), or umbilical cord tissue.

A major global trend in mesenchymal stem cell (MSC) therapy is a move towards personalized and precision medicine techniques. As regenerative medicine research progresses, there is an increasing knowledge of the variability of MSC populations derived from various tissues and donors, resulting in personalized therapies for specific reasons and patients.

Furthermore, there is a growing emphasis on optimizing production and delivery techniques to improve the safety, effectiveness, and scalability of MSC treatments. Moreover, academic, industrial, and regulatory organizations are working together to promote standardized protocols, quality assurance techniques, and regulatory frameworks to ensure clinical application uniformity and safety.

Additionally, studies into novel delivery modalities, such as exosome-based therapeutics produced from MSCs, provide a promising route for improving therapeutic effects while reducing possible hazards. Overall, these trends reflect a dynamic landscape in MSC therapy characterized by personalized approaches, technological advancements, and regulatory harmonization efforts.

By type, allogeneic segment held the highest market share in 2023 and is expected to keep its dominance during the forecast period 2024-2033. A major development in allogeneic mesenchymal stem cell therapy is an increased emphasis on off-the-shelf treatments that use donor-derived cells for more application, shorter patient wait periods, and easier treatment access.

By source of isolation, the bone marrow segment held the highest market share in 2023 and is expected to keep its dominance during the forecast period 2024-2033. One trend in bone marrow research and therapy is the growing emphasis on mesenchymal stem cells produced from bone marrow for regenerative medicine applications, such as treating orthopedic disorders and autoimmune illnesses.

By application, the disease modelling segment held the highest market share in 2023 and is expected to keep its dominance during the forecast period 2024-2033.  A significant trend in disease modelling is the increased use of modern technologies such as organoids, induced pluripotent stem cells, and CRISPR-Cas9 gene editing to properly simulate complex human illnesses in vitro for research and drug development reasons.

In North America, there is a noticeable trend of increased usage of mesenchymal stem cell treatment, which is being driven by advances in research, supporting regulatory frameworks, and growing acceptability among doctors and patients.

Mesoblast uses its patented mesenchymal lineage cell technology platform to create and commercialize new allogeneic cellular therapeutics to treat complicated inflammatory disorders that are resistant to traditional treatments.

Report Scope

CMI has comprehensively analyzed the Global Mesenchymal Stem Cell Therapy market. The driving forces, restraints, challenges, opportunities, and key trends have been explained in depth to depict depth scenarios of the market. Segment wise market size and market share during the forecast period are duly addressed to portray the probable picture of this Global Mesenchymal Stem Cell Therapy industry.

The competitive landscape includes key innovators, after market service providers, market giants as well as niche players are studied and analyzed extensively concerning their strengths, weaknesses as well as value addition prospects. In addition, this report covers key players profiling, market shares, mergers and acquisitions, consequent market fragmentation, new trends and dynamics in partnerships.

List of the prominent players in the Mesenchymal Stem Cell Therapy Market:

• Mesoblast Limited
• TiGenix
• Osiris Therapeutics
• Celgene Corporation
• Vericel Corporation
• Athersys Inc.
• NuVasive Inc.
• Orthofix Medical Inc.
• Regeneus Ltd.
• Pluristem Therapeutics Inc.
• ReNeuron Group plc
• Anterogen Co. Ltd.
• Pharmicell Co. Ltd.
• Cytori Therapeutics Inc.
• Mesoblast Limited
• Stempeutics Research Pvt. Ltd.
• Mesenchymal Stem Cells of Georgia LLC
• Capricor Therapeutics
• Celltex Therapeutics Corporation
• Cells for Cells S.A.
• Others

The Mesenchymal Stem Cell Therapy Market is segmented as follows:

By Type

• Autologous
• Allogeneic

By Source of Isolation

• Bone Marrow
• Cord Blood
• Peripheral Blood
• Fallopian Tube
• Fetal Liver
• Lung
• Adipose Tissues

By Application

• Disease Modelling
• Drug Development & Discovery
• Stem Cell Banking
• Tissue Engineering
• Toxicology Studies
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America